Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia

Background: Schizophrenia is associated with high direct healthcare costs due to progression of disease and frequent occurrence of relapses. Aripiprazole once-monthly (AOM) has been shown to reduce total psychiatric hospitalizations among patients who switched from oral standard of care (SOC) therap...

Full description

Bibliographic Details
Main Authors: Michele Wilson, Benjamin Gutierrez, Steve J Offord, Christopher M Blanchette, Anna Eramo, Stephanie Earnshaw, Siddhesh A Kamat
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2016-03-01
Series:Drugs in Context
Subjects:
schizophrenia
long-acting injectable
economic model
aripiprazole once-monthly
relapse
healthcare cost
Online Access:http://www.drugsincontext.com/inpatient-resource-use-and-costs-associated-with-switching-from-oral-antipsychotics-to-aripiprazole-once-monthly-for-the-treatment-of-schizophrenia/

Internet

http://www.drugsincontext.com/inpatient-resource-use-and-costs-associated-with-switching-from-oral-antipsychotics-to-aripiprazole-once-monthly-for-the-treatment-of-schizophrenia/

Similar Items